Children with High Risk Neuroblastoma: Prophylactic and Therapeutic Treatment with Docosahexaenoic Acid

Chapter
Part of the Pediatric Cancer book series (PECA, volume 4)

Abstract

Despite intense multimodal treatment of neuroblastoma consisting of surgery, chemotherapy, radiotherapy, and stem cell rescue, long-term survival is only 50% in the high-risk group. We therefore need to improve existing treatment protocols and search for new medications.

Inflammation drives cancer growth, and targeted therapy that dampens inflammatory responses is anti-proliferative. The inducible COX-2 enzyme that converts the omega-6 fatty acid arachidonic acid (AA) to various inflammatory prostaglandins is up-regulated in neuroblastoma tissue. Non steroidal anti-inflammatory drugs (NSAIDs) that inhibit prostaglandin synthesis have profound growth inhibitory effects on neuroblastoma cells in preclinical models.

Omega-3 fatty acids oppose the effects of omega-6 fatty acids and have been implicated in cancer treatment and prevention. Omega-3 fatty acids such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) are precursors of anti-inflammatory compounds. From DHA and EPA resolvins and protectins are produced, which are potent pro-resolving lipid mediators essential for the clearance of inflammatory cells and mediators at an injured site.

This chapter will discuss the toxicity of DHA to neuroblastoma cells both in vivo and in vitro as well as discuss the effects of DHA in clinical trials of various cancers. In vivo, DHA is able to delay time to tumor development and reduce tumor growth in neuroblastoma xenograft models. In vitro, DHA acts by inducing mitochondrial-dependent apoptosis of neuroblastoma cell lines. In addition, clinical studies show that DHA acts in synergy with chemotherapy.

In summary, this chapter shows that omega-3 fatty acids such as DHA are possible new agents for neuroblastoma prevention and treatment, and suggests that these compounds be tested in clinical trials as adjuvant therapy to chemotherapeutic drugs in children with neuroblastoma.

Keywords

Arachidonic Acid Neuroblastoma Cell Docosahexaenoic Acid Lipid Mediator Radical Oxygen Species 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Bang HO, Dyerberg J, Nielsen AB (1971) Plasma lipid and lipoprotein pattern in Greenlandic west-coast Eskimos. Lancet 1(7710):1143–1145PubMedCrossRefGoogle Scholar
  2. Barnes CM, Prox D, Christison-Lagay EA, Le HD, Short S, Cassiola F, Panigrahy D, Chaponis D, Butterfield C, Nehra D, Fallon EM, Kieran M, Folkman J, Puder M (2012) Inhibition of neuroblastoma cell proliferation with omega-3 fatty acids and treatment of a murine model of human neuroblastoma using a diet enriched with omega-3 fatty acids in combination with sunitinib. Pediatr Res 71(2):168–1678PubMedCrossRefGoogle Scholar
  3. Baryawno N, Sveinbjornsson B, Eksborg S, Orrego A, Segerstrom L, Oqvist CO, Holm S, Gustavsson B, Kagedal B, Kogner P, Johnsen JI (2008) Tumor-growth-promoting cyclooxygenase-2 prostaglandin e2 pathway provides medulloblastoma therapeutic targets. Neuro Oncol 10(5):661–674PubMedCrossRefGoogle Scholar
  4. Berquin IM, Edwards IJ, Chen YQ (2008) Multi-targeted therapy of cancer by omega-3 fatty acids. Cancer Lett 269(2):363–377PubMedCrossRefGoogle Scholar
  5. Biondo PD, Brindley DN, Sawyer MB, Field CJ (2008) The potential for treatment with dietary long-chain polyunsaturated n-3 fatty acids during chemotherapy. J Nutr Biochem 19(12):787–796PubMedCrossRefGoogle Scholar
  6. Bougnoux P, Hajjaji N, Ferrasson MN, Giraudeau B, Couet C, Le Floch O (2009) Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase ii trial. Br J Cancer 101(12):1978–1985PubMedCrossRefGoogle Scholar
  7. D’Eliseo D, Manzi L, Merendino N, Velotti F (2011) Docosahexaenoic acid inhibits invasion of human rt112 urinary bladder and pt45 pancreatic carcinoma cells via down-modulation of granzyme b expression. J Nutr Biochem 23:452–457PubMedCrossRefGoogle Scholar
  8. Farooqui AA (2012) N-3 fatty acid-derived lipid mediators in the brain: new weapons against oxidative stress and inflammation. Curr Med Chem 19(4):532–543PubMedCrossRefGoogle Scholar
  9. Finocchiaro C, Segre O, Fadda M, Monge T, Scigliano M, Schena M, Tinivella M, Tiozzo E, Catalano MG, Pugliese M, Fortunati N, Aragno M, Muzio G, Maggiora M, Oraldi M, Canuto RA (2011) Effect of n-3 fatty acids on patients with advanced lung cancer: a double-blind, placebo-controlled study. Br J Nutr 108:327–333Google Scholar
  10. Gani OA, Sylte I (2008) Molecular recognition of docosahexaenoic acid by peroxisome proliferator-activated receptors and retinoid-x receptor alpha. J Mol Graph Model 27(2):217–224PubMedCrossRefGoogle Scholar
  11. Gleissman H, Yang R, Martinod K, Lindskog M, Serhan CN, Johnsen JI, Kogner P (2009) Docosahexaenoic acid metabolome in neural tumors: identification of cytotoxic intermediates. FASEB J 24(3):906–915PubMedCrossRefGoogle Scholar
  12. Gleissman H, Johnsen JI, Kogner P (2010a) Omega-3 fatty acids in cancer, the protectors of good and the killers of evil? Exp Cell Res 316(8):1365–1373PubMedCrossRefGoogle Scholar
  13. Gleissman H, Segerstrom L, Hamberg M, Ponthan F, Lindskog M, Johnsen JI, Kogner P (2010b) Omega-3 fatty acid supplementation delays the progression of neuroblastoma in vivo. Int J Cancer 128(7):1703–1711PubMedCrossRefGoogle Scholar
  14. Jude S, Roger S, Martel E, Besson P, Richard S, Bougnoux P, Champeroux P, Le Guennec JY (2006) Dietary long-chain omega-3 fatty acids of marine origin: a comparison of their protective effects on coronary heart disease and breast cancers. Prog Biophys Mol Biol 90(1–3):299–325PubMedCrossRefGoogle Scholar
  15. Kang JX, Wang J, Wu L, Kang ZB (2004) Transgenic mice: fat-1 mice convert n-6 to n-3 fatty acids. Nature 427(6974):504PubMedCrossRefGoogle Scholar
  16. Lanier AP, Holck P, Ehrsam Day G, Key C (2003) Childhood cancer among Alaska natives. Pediatrics 112(5):e396PubMedCrossRefGoogle Scholar
  17. Larsson SC, Kumlin M, Ingelman-Sundberg M, Wolk A (2004) Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am J Clin Nutr 79(6):935–945PubMedGoogle Scholar
  18. Lengqvist J, Mata De Urquiza A, Bergman AC, Willson TM, Sjovall J, Perlmann T, Griffiths WJ (2004) Polyunsaturated fatty acids including docosahexaenoic and arachidonic acid bind to the retinoid × receptor alpha ligand-binding domain. Mol Cell Proteomics 3(7):692–703PubMedCrossRefGoogle Scholar
  19. Lien EL (2009) Toxicology and safety of DHA. Prostaglandins Leukot Essent Fat Acids 81(2–3):125–132CrossRefGoogle Scholar
  20. Lindskog M, Gleissman H, Ponthan F, Castro J, Kogner P, Johnsen JI (2006) Neuroblastoma cell death in response to docosahexaenoic acid: sensitization to chemotherapy and arsenic-induced oxidative stress. Int J Cancer 118(10):2584–2593PubMedCrossRefGoogle Scholar
  21. Mandal CC, Ghosh-Choudhury T, Yoneda T, Choudhury GG, Ghosh-Choudhury N (2010) Fish oil prevents breast cancer cell metastasis to bone. Biochem Biophys Res Commun 402(4):602–607PubMedCrossRefGoogle Scholar
  22. Manna S, Chakraborty T, Ghosh B, Chatterjee M, Panda A, Srivastava S, Rana A, Chatterjee M (2008) Dietary fish oil associated with increased apoptosis and modulated expression of bax and bcl-2 during 7, 12-dimethylbenz(alpha)anthracene-induced mammary carcinogenesis in rats. Prostaglandins Leukot Essent Fat Acids 79(1–2):5–14CrossRefGoogle Scholar
  23. Manson JE, Bassuk SS, Lee IM, Cook NR, Albert MA, Gordon D, Zaharris E, Macfadyen JG, Danielson E, Lin J, Zhang SM, Buring JE (2011) The vitamin d and omega-3 trial (vital): rationale and design of a large randomized controlled trial of vitamin d and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials 33(1):159–171PubMedCrossRefGoogle Scholar
  24. Murphy RA, Mourtzakis M, Chu QS, Baracos VE, Reiman T, Mazurak VC (2011) Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer. Cancer 117(16):3774–3780PubMedCrossRefGoogle Scholar
  25. Piomelli D, Astarita G, Rapaka R (2007) A neuroscientist’s guide to lipidomics. Nat Rev Neurosci 8(10):743–754PubMedCrossRefGoogle Scholar
  26. Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, Moussignac RL (2002) Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 196(8):1025–1037PubMedCrossRefGoogle Scholar
  27. Serhan CN, Chiang N, Van Dyke TE (2008) Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 8(5):349–361PubMedCrossRefGoogle Scholar
  28. Serini S, Piccioni E, Merendino N, Calviello G (2009) Dietary polyunsaturated fatty acids as inducers of apoptosis: implications for cancer. Apoptosis 14(2):135–152PubMedCrossRefGoogle Scholar
  29. Siddiqui RA, Harvey K, Stillwell W (2008) Anticancer properties of oxidation products of docosahexaenoic acid. Chem Phys Lipids 153(1):47–56PubMedCrossRefGoogle Scholar
  30. Siddiqui RA, Harvey KA, Xu Z, Bammerlin EM, Walker C, Altenburg JD (2011) Docosahexaenoic acid: a natural powerful adjuvant that improves efficacy for anticancer treatment with no adverse effects. Biofactors 37(6):399–412PubMedCrossRefGoogle Scholar
  31. Simopoulos AP (2006) Evolutionary aspects of diet, the omega-6/omega-3 ratio and genetic variation: nutritional implications for chronic diseases. Biomed Pharmacother 60(9):502–507PubMedCrossRefGoogle Scholar
  32. Stillwell W, Wassall SR (2003) Docosahexaenoic acid: membrane properties of a unique fatty acid. Chem Phys Lipids 126(1):1–27PubMedCrossRefGoogle Scholar
  33. van der Meij BS, Langius JA, Spreeuwenberg MD, Slootmaker SM, Paul MA, Smit EF, van Leeuwen PA (2012) Oral nutritional supplements containing n-3 polyunsaturated fatty acids affect quality of life and functional status in lung cancer patients during multimodality treatment: an RCT. Eur J Clin Nutr 66:399–404PubMedCrossRefGoogle Scholar
  34. Victory R, Saed GM, Diamond MP (2007) Antiadhesion effects of docosahexaenoic acid on normal human peritoneal and adhesion fibroblasts. Fertil Steril 88(6):1657–1662PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  1. 1.Childhood Cancer Research Unit, Q6:05, Department of Women’s and Children’s HealthKarolinska InstitutetStockholmSweden

Personalised recommendations